What is Argos Therapeutics' stock symbol?
Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."
Where is Argos Therapeutics' stock going? Where will Argos Therapeutics' stock price be in 2017?
7 brokerages have issued 12-month price targets for Argos Therapeutics' shares. Their forecasts range from $10.00 to $18.00. On average, they expect Argos Therapeutics' stock price to reach $12.29 in the next twelve months.
When will Argos Therapeutics announce their earnings?
Argos Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.
What are analysts saying about Argos Therapeutics stock?
Here are some recent quotes from research analysts about Argos Therapeutics stock:
According to Zacks Investment Research, "Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. " (2/7/2017)
FBR & Co analysts commented, "We had the opportunity to meet with Argos management and discuss the company outlook and pipeline goals for 2017. As a reminder, Argos is currently conducting a Phase III ADAPT trial in renal cell cancer (RCC). We expect data in June and estimate the company will file a BLA in 1Q18, followed by a potential FDA approval and commercial launch in late 2018." (1/17/2017)
Who owns Argos Therapeutics stock?
Argos Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (0.43%), Wall Street Associates (0.20%) and Keybank National Association OH (0.06%). Company insiders that own Argos Therapeutics stock include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom.
Who sold Argos Therapeutics stock? Who is selling Argos Therapeutics stock?
Argos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates.
Who bought Argos Therapeutics stock? Who is buying Argos Therapeutics stock?
Argos Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have bought Argos Therapeutics stock in the last two years include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom.
How do I buy Argos Therapeutics stock?
Shares of Argos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Argos Therapeutics stock cost?
One share of Argos Therapeutics stock can currently be purchased for approximately $4.70.